Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy

Johnson, K.C.; Aragaki, A.K.; Jackson, R.; Reiner, A.; Sandset, P.M.; Rosing, J.; ... ; Rossouw, J.E. (2016)

Article / Letter to editor

• activated protein C resistance
• coronary disease
• estrogens
• hemostatics
• progestins
• tissue factor pathway inhibitor activity

• All authors: Johnson, K.C.; Aragaki, A.K.; Jackson, R.; Reiner, A.; Sandset, P.M.; Rosing, J.; Dahm, A.E.A.; Rosendaal, F.; Manson, J.E.; Martin, L.W.; Liu, S.M.; Kuller, L.H.; Cushman, M.; Rossouw, J.E.
• Date: 2016-02-28
• Journal: Arteriosclerosis, Thrombosis, and Vascular Biology
• Volume: 36
• Issue: 2
• Pages: 418 - 424
• DOI: doi:10.1161/ATVBAHA.115.306905